New treatment for HR-negative, HER2-low breast cancer before surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (SHR-A1811 and Adebrelimab) given before surgery to women with a certain type of breast cancer that is hormone receptor (HR) negative or low and HER2 low. The goal is to see if this treatment can shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have not received any treatment for your breast cancer yet.
- Your breast cancer is stage II or III and the tumor is larger than 2 cm.
- Your breast cancer type is HR-negative or HR-low and HER2-low (your doctor can check this).
- You are generally healthy enough for treatment (no major heart, lung, kidney, or liver problems).
- You agree to use effective birth control and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new immunotherapy drug (adebrelimab) and a targeted therapy (T-DXd) to standard chemotherapy works better than chemotherapy alone for early-stage HR+/HER2-low breast cancer before surgery. It aims to shrink the tumor and reduce the chance of cancer coming back.
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests adding a drug called adebrelimab to standard chemotherapy and possibly radiation, given before surgery for breast cancer that is HER2-negative and locally advanced. The goal is to see if this combination helps shrink tumors more effectively, potentially allowing for breast-conserving surgery.
This study tests a new drug called SHR-A1811 in patients with advanced breast cancer that has a protein called HER2. The drug may help slow or stop cancer growth in patients who haven't had too many prior treatments.
This trial tests a new drug (SHR-A1811) alone or with another drug (adebrelimab) before surgery for women with a specific type of early-stage breast cancer called HR+, HER2-low. The goal is to see if this combination can shrink the tumor before surgery, possibly leading to better outcomes.
This trial tests a combination of two drugs—SHR-A1921 (a targeted therapy) and Adebrelimab (an immunotherapy)—for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, PD-L1 positive). It aims to see if this combo can help when hormone therapy and chemotherapy haven't worked well enough.
Hear when a new Untreated Early-stage or Locally Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.